USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Medarex, Inc.
Address:
707 State Road
Princeton, NJ 08540
Phone:
(908) 479-2464
URL:
N/A
EIN:
222822175
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $875,908.00 8
SBIR Phase II $684,590.00 1
STTR Phase I $200,000.00 3
STTR Phase II $264,820.00 1

Award List:

IFN-GAMMA BIOASSAYS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Ifn- is currently being tested for the treatment of a wide range of diseases including autoimmune and infectious diseases, solid tumors and hematologic malignancies. as with other biological response modifiers, it is difficult to predict the optimal dose for the desired in vivo effect, and two… More

ELIMINATION OF ANTIGEN REACTIVE B CELLS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Medarex has exclusive license to several monoclonal antibodies (mabs) reactive to the high affinity fc receptor for igg (fcgri), on human monocytes. this receptor is a critical trigger molecule for adcc by these cells and has been shown to mediate killing of red cell targets and tumor like cells. we… More

BI-SPECIFIC ANTIBODY-DIRECTED KILLING IN HIV THERAPY

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ateeq Ahmad
Abstract:
Medarex, inc., has exclusive license to several monoclonal antibodies (mabs) reactive to the high-affinity fc receptor for igg (fc ri), which is expressed on human monocytes and, after ifn activation, on human pmns. this receptor is a critical trigger molecule for adcc by these cells. this research… More

REDIRECTING THE IMMUNE SYSTEM FOR ANTICANCER THERAPY

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$53,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

DEVELOPMENT OF A NOVEL VACCINE STRATEGY

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$64,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

REDIRECTING THE IMMUNE SYSTEM FOR ANTICANCER THERAPY

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$684,590.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

TWO COMPONENT STRATEGY FOR IMMUNE TARGETING

Award Year / Program / Phase:
1998 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Gosselin
Research Institution:
Albany Medical College
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / STTR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Ely
Research Institution:
Dartmouth College
RI Contact:
N/A
Abstract:
N/a

ANTIBODY THERAPY FOR STAPHYLOCOCUUS AUREUS INFECTIONS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Tibor P. Keler
Abstract:
Not Available This program will develop high-power visible laser sources based on frequency conversion of 1 micron diode-pumped solid-state lasers. Improvements are needed in efficient and robust nonlinear materials. The technical objectives of our overall research program are to develop… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Tibor P. Keler
Abstract:
N/a

An improved targeted vaccine strategy against anthrax

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$408,908.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this proposal is to develop a novel targeted vaccine technology against emerging infectious diseases and pathogens associated with bioterrorism. Previous studies have documented the extremely rapid and potent immune responses elicited by… More